

# Daniela-Elena Oprea-Lager

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2129978/publications.pdf>

Version: 2024-02-01

74  
papers

3,831  
citations

304368

22  
h-index

138251

58  
g-index

77  
all docs

77  
docs citations

77  
times ranked

3694  
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€™2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	0.9	1,545
2	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€™2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	0.9	633
3	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	3.3	188
4	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 469-476.	3.3	119
5	Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. European Journal of Cancer, 2018, 91, 153-163.	1.3	107
6	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98
7	Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 340-349.	3.3	84
8	Quantification of PD-L1 Expression with <sup>18</sup> F-BMS-986192 PET/CT in Patients with Advanced-Stage Nonâ€™Small Cell Lung Cancer. Journal of Nuclear Medicine, 2020, 61, 1455-1460.	2.8	54
9	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. European Urology, 2016, 70, 416-426.	0.9	51
10	Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. European Urology Oncology, 2021, 4, 821-825.	2.6	42
11	The Role of <sup>89</sup> Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. Journal of Nuclear Medicine, 2021, 62, 438-445.	2.8	39
12	Quantitative implications of the updated EARL 2019 PETâ€™CT performance standards. EJNMMI Physics, 2019, 6, 28.	1.3	37
13	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. European Urology, 2021, 80, 234-242.	0.9	35
14	Dual-Phase PET-CT to Differentiate [18F]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in Patients with Prostate Cancer. PLoS ONE, 2012, 7, e48430.	1.1	33
15	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clinical Genitourinary Cancer, 2017, 15, e773-e782.	0.9	33
16	Quantification of <sup>18</sup> F-Fluorocholine Kinetics in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 365-371.	2.8	32
17	Simplified Methods for Quantification of <sup>18</sup> F-DCFPyL Uptake in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1730-1735.	2.8	32
18	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer, 2020, 20, 884.	1.1	32

#	ARTICLE	IF	CITATIONS
19	ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro. <i>Anticancer Research</i> , 2013, 33, 387-91.	0.5	32
20	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. <i>European Urology Oncology</i> , 2020, 3, 231-238.	2.6	30
21	Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1642-1649.	2.8	28
22	Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. <i>World Journal of Urology</i> , 2021, 39, 2439-2446.	1.2	26
23	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	2.6	26
24	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	2.8	23
25	Repeatability of Quantitative <sup>18</sup> F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 721-727.	2.8	22
26	Repeatability of Quantitative <sup>18</sup> F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1320-1325.	2.8	22
27	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	1.6	21
28	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	0.9	21
29	Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 181.e1-181.e6.	0.8	18
30	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. <i>BMC Cancer</i> , 2020, 20, 764.	1.1	18
31	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. <i>Cancers</i> , 2021, 13, 3902.	1.7	18
32	Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. <i>Liver Transplantation</i> , 2011, 17, 261-269.	1.3	17
33	The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases. <i>BMC Medical Imaging</i> , 2014, 14, 27.	1.4	17
34	Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: A feasibility study. <i>European Journal of Radiology</i> , 2014, 83, 1144-1151.	1.2	16
35	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1319-1327.	3.3	15
36	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. <i>Cancers</i> , 2022, 14, 1169.	1.7	15

#	ARTICLE	IF	CITATIONS
37	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. <i>Frontiers in Oncology</i> , 2021, 11, 772530.	1.3	14
38	Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1731-1742.	3.3	13
39	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	0.7	13
40	Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 406-410.	0.4	11
41	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.252528.	2.8	11
42	Impact of the COVID-19 crisis on imaging in oncological trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2054-2058.	3.3	11
43	A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems. <i>Molecular Imaging and Biology</i> , 2015, 17, 714-725.	1.3	10
44	[18F]Fluoromethylcholine as a Chemotherapy Response Read-Out in Prostate Cancer Cells. <i>Molecular Imaging and Biology</i> , 2015, 17, 319-327.	1.3	10
45	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70.	1.1	10
46	Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for <sup>18</sup> F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 210-216.	2.8	10
47	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	1.6	10
48	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1655-1662.	0.2	10
49	Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. <i>BJU International</i> , 2022, 129, 54-62.	1.3	10
50	Diagnostic Performance of [18F]FDG PET in Staging Grade 1-2, Estrogen Receptor Positive Breast Cancer. <i>Diagnostics</i> , 2021, 11, 1954.	1.3	10
51	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6. <i>European Urology</i> , 2020, 78, 310-313.	0.9	9
52	M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting. <i>BJUI Compass</i> , 2021, 2, 159-168.	0.7	8
53	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2960-2969.	3.3	8
54	Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim <sup>18</sup> F-FDG PET in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1531-1536.	2.8	8

#	ARTICLE	IF	CITATIONS
55	Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 6164.	1.7	8
56	Health technology assessment for PSMA-PET: striving towards a cost-effective management of prostate cancer. <i>Clinical and Translational Imaging</i> , 2021, 9, 409-412.	1.1	7
57	Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. <i>BJU International</i> , 2022, 129, 768-776.	1.3	7
58	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. <i>Diagnostics</i> , 2021, 11, 117.	1.3	6
59	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239414.	1.1	6
60	The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography. <i>BJU International</i> , 2022, 129, 314-317.	1.3	6
61	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1100-1109.	0.2	4
62	Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?. <i>European Urology</i> , 2022, 81, 319-322.	0.9	4
63	First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using <sup>89</sup> Zr-Df-CPC634 PET/CT.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3093-3093.	0.8	3
64	SUVs Are Adequate Measures of Lesional <sup>18</sup> F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1264-1269.	2.8	2
65	External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyL: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?. <i>European Urology Open Science</i> , 2021, 28, 47-51.	0.2	2
66	Biodistribution of <sup>18</sup> F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262500.	2.8	2
67	PET-Guided Stereotactic Irradiation of Prostate Cancer Lymph Node Metastases. <i>Journal of Nuclear Medicine</i> , 2017, 58, 183-184.	2.8	1
68	Reply: Quantification of <sup>18</sup> F-DCFPyL Uptake: TBR Versus Patlak's Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1834.2-1835.	2.8	1
69	A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5081-5081.	0.8	1
70	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1108-1109.	0.2	0
71	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1662-1662.	0.2	0
72	MP13-13â€f VALIDITY OF 18F-PROSTATE-SPECIFIC MEMBRANE ANTIGEN PET/CT DETECTED LESIONS IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER IN CLINICAL PRACTICE. <i>Journal of Urology</i> , 2020, 203, e189.	0.2	0

#	ARTICLE	IF	CITATIONS
73	MP53-14â€fPATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND A LOCAL RECURRENCE OR NEGATIVE PSMA PET/CT ARE EXCELLENT CANDIDATES FOR SALVAGE RADIOTHERAPY TO THE PROSTATIC FOSSA. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
74	Abstract 1415: Staging with [18F]FDG PET/CT., 2019, ,.		0